Applied DNA Sciences Shares Up 13% on Licensing Deal >APDN
Applied DNA Sciences Shares Up 13% on Licensing Deal >APDN
DJ Applied DNA Sciences Shares Up 13% on Licensing Deal >APDN
By Chris Wack
Applied DNA Sciences Inc. (APDN) shares rose 13% to $4.52 premarket after the company said its LineaRx Inc. subsidiary has signed a licensing agreement with LifeSensors Inc. to incorporate LifeSensors' high expression SUMO-fusion technologies into the company's linear DNA amplicons designed and produced for therapeutic applications.
Applied DNA said LineaRx will have a worldwide license to the applicable LifeSensors intellectual property to make, have made, use, and sell DNA constructs incorporating the SUMO-fusion technologies for therapeutic and diagnostic applications.
The companies said they will work together on initially developing and releasing two high expression amplicons: one for the generic Luciferase protein and one for its licensed anti-CD19 therapy.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
January 13, 2020 09:25 ET (14:25 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
DJ Applied DNA Sciences Shares Up 13% on Licensing Deal >APDN
DJ應用DNA Sciences在授權交易>APDN上上漲13%
By Chris Wack
克里斯·瓦克(Chris Wack)著
Applied DNA Sciences Inc. (APDN) shares rose 13% to $4.52 premarket after the company said its LineaRx Inc. subsidiary has signed a licensing agreement with LifeSensors Inc. to incorporate LifeSensors' high expression SUMO-fusion technologies into the company's linear DNA amplicons designed and produced for therapeutic applications.
應用DNA科學公司(APDN)股價盤前上漲13%，至4.52美元，此前該公司表示，其子公司LineaRx Inc.已經與Lifesensors Inc.簽署了一項許可協議，將Lifesensors的高表達相撲融合技術納入該公司為治療應用設計和生產的線性DNA擴增器中。
Applied DNA said LineaRx will have a worldwide license to the applicable LifeSensors intellectual property to make, have made, use, and sell DNA constructs incorporating the SUMO-fusion technologies for therapeutic and diagnostic applications.
應用DNA公司表示，LineaRx將擁有適用的Lifesensors知識產權的全球許可，可以製造、製造、使用和銷售包含相撲融合技術的DNA結構，用於治療和診斷應用。
The companies said they will work together on initially developing and releasing two high expression amplicons: one for the generic Luciferase protein and one for its licensed anti-CD19 therapy.
兩家公司表示，他們將合作最初開發和釋放兩種高表達擴增物：一種用於通用熒光素酶蛋白，另一種用於獲得許可的抗CD19療法。
Write to Chris Wack at chris.wack@wsj.com
寫信給克里斯·瓦克(chris.wack@wsj.com)
(END) Dow Jones Newswires
(完)道瓊通訊社
January 13, 2020 09:25 ET (14:25 GMT)
2020年1月13日東部時間09：25(格林尼治標準時間14：25)
Copyright (c) 2020 Dow Jones & Company, Inc.
版權所有(C)2020道瓊斯公司。
譯文內容由第三人軟體翻譯。
風險及免責聲明
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧